Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Gutmann

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Communications Chemistry|January 25, 2023
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistancePhilipp Fronik, Michael Gutmann, Petra Vician, et al.
Inorganic Chemistry Frontiers|April 7, 2025
Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonistsMartijn Dijkstra, Michael Gutmann, Mathias Gradl, et al.
Journal of Theoretical Biology|February 27, 2016
The impact of host metapopulation structure on the population genetics of colonizing bacteriaElina Numminen, Michael Gutmann, Mikhail Shubin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 13, 2026
Improved Systemic Immunochemotherapy Employing an Oxaliplatin-TLR7/8 Agonist Prodrug StrategyMichael Gutmann, Martijn Dijkstra, Philipp Salomon, et al.
European Urology Oncology|May 16, 2024
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer ModelsMichael Gutmann, Iris E Ertl, Paula Herek, et al.
European Urology|April 8, 2022
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active CompoundIris E Ertl, Ursula Lemberger, Dafina Ilijazi, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Communications Chemistry|January 25, 2023
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistancePhilipp Fronik, Michael Gutmann, Petra Vician, et al.
Inorganic Chemistry Frontiers|April 7, 2025
Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonistsMartijn Dijkstra, Michael Gutmann, Mathias Gradl, et al.
Journal of Theoretical Biology|February 27, 2016
The impact of host metapopulation structure on the population genetics of colonizing bacteriaElina Numminen, Michael Gutmann, Mikhail Shubin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 13, 2026
Improved Systemic Immunochemotherapy Employing an Oxaliplatin-TLR7/8 Agonist Prodrug StrategyMichael Gutmann, Martijn Dijkstra, Philipp Salomon, et al.
European Urology Oncology|May 16, 2024
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer ModelsMichael Gutmann, Iris E Ertl, Paula Herek, et al.
European Urology|April 8, 2022
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active CompoundIris E Ertl, Ursula Lemberger, Dafina Ilijazi, et al.
Pageof 2